{
    "name": "PEG tube feeding",
    "model_uri": "https://www.predictcancer.ai/Main.php?page=TFDInfo",
    "full_model_name": "Prediction model for tube feeding dependency during chemoradiotherapy for at least four weeks in head and neck cancer patients",
    "intercept": -0.506,
    "covariate_weights": {
        "BMI": -0.042,
        "WeightLoss": -0.03,
        "TF": 0.452,
        "PS": 0.608,
        "Tumorlocation": -0.51,
        "Tclassification": 0.311,
        "Nclassification": 0.561,
        "Systherapy": -0.655,
        "RTdose_subman": 0.015,
        "RTdosesalivary": 0.042
    },
    "List of essential  metrics": [
        "PPV",
        "NPV",
        "Calibration"
    ],
    "Performance metrics": {
        "AUC": "74.8% (95% CI  70.1-79.6%)",
        "PPV": "90%",
        "NPV": "64%"
    },
    "outcome": {
        "description": "Prediction to identify patients who need prophylactic gastrostomy insertion for at least four weeks",
        "type": "numerical",
        "code": "61420007",
        "terminology": "SNOMEDCT"
    },
    "features": {
        "BMI": {
            "description": "Body mass index",
            "type": "numerical",
            "code": "Z68",
            "terminology": "ICD10CM"
        },
        "WeightLoss": {
            "description": "Weight change finding",
            "type": "numerical",
            "code": "365921005",
            "terminology": "SNOMEDCT"
        },
        "TF": {
            "description": "Texture modified diet or tube feeding",
            "type": "categorical",
            "code": "435801000124108",
            "terminology": "SNOMEDCT",
            "values": {
                "yes": 1,
                "no": 0
            }
        },
        "PS": {
            "description": "WHO performance status finding",
            "type": "categorical",
            "code": "373802001",
            "terminology": "SNOMEDCT",
            "values": {
                "373803006": 0,
                "373804000": 1,
                "373805004": 1,
                "373806003": 1,
                "373807007": 1
            }
        },
        "Tumorlocation": {
            "description": "Tumor location",
            "type": "categorical",
            "code": "C182223",
            "terminology": "NCI_Thesaurus",
            "values": 0
        },
        "Tclassification": {
            "description": "Tumor stage finding",
            "type": "categorical",
            "code": "385356007",
            "terminology": "SNOMEDCT",
            "values": 0
        },
        "Nclassification": {
            "description": "N - Regional lymph node stage",
            "type": "categorical",
            "code": "260767000",
            "terminology": "SNOMEDCT",
            "values": 0
        },
        "Systherapy": {
            "description": "Systemic Therapy",
            "type": "categorical",
            "code": "C15698",
            "terminology": "NCI_Thesaurus",
            "values": 0
        },
        "RTdose_subman": {
            "description": "Mean Radiation Dose on contralateral submandibular gland [Gy]",
            "type": "numerical",
            "code": "C190594",
            "terminology": "NCI_Thesaurus"
        },
        "RTdosesalivary": {
            "description": "Mean Radiation Dose contralateral parotid salivary gland [Gy]",
            "type": "numerical",
            "code": "C190594",
            "terminology": "NCI_Thesaurus"
        }
    },
    "Description": "Model for predicting the prophylactic gastronomy insertion (tube feeding) for at least four weeks in head and neck cancer patients undergoing chemoradiotherapy",
    "Applicability criteria": "Patients diagnosed with locally advanced head and neck squamous cell carcinoma (LAHNSCC). Patients undergoing chemoradiotherapy (CRT) or bioradiotherapy (BRT) with curative intent. Patients who are starting primary or adjuvant radiotherapy combined with either cisplatin, carboplatin, or cetuximab.",
    "Primary intended use": "To support personalized decision-making on prophylactic gastrostomy insertion in head and neck cancer patients undergoing chemoradiotherapy.",
    "Primary intended users": "Clinicians and healthcare providers treating head and neck cancer patients."
}